Why Enovis stock is back in focus after its latest results
Enovis (ENOV) has come back onto investors’ radar after reporting fourth quarter and full year 2025 results that combined continued net losses, sizeable goodwill impairment charges, and fresh 2026 revenue guidance.
See our latest analysis for Enovis.
Following the earnings release and goodwill impairment news on 26 February, Enovis’ share price has seen a 1 day share price return of 0.78% and a 1 month share price return of 8.5%. However, its 1 year total shareholder return of 30.98% and 5 year total shareholder return of 71.31% highlight that momentum has been weak over longer periods as investors reassess ongoing losses and the new 2026 revenue outlook.
If this mix of losses, guidance and conference updates has you reassessing your watchlist, it could be a good moment to look at 32 healthcare AI stocks as potential alternatives in the broader medical and healthcare space.
With the share price well below analyst targets but the business still reporting sizeable losses and goodwill charges, is Enovis being priced too harshly today, or is the market already baking in all the future growth it sees?
Most Popular Narrative: 45.6% Undervalued
With Enovis last closing at $24.51 versus a narrative fair value of $45.09, the most followed storyline in the market sees a wide valuation gap that hinges on future cash generation and margin progress.
Operational excellence initiatives, including adoption of a disciplined business system (EGX), targeted resource allocation, and optimization of manufacturing and supply chain, are driving ongoing gross margin expansion and improved free cash flow conversion, supporting improved earnings and deleveraging despite near-term headwinds (for example, tariffs).
Curious how a loss making company gets to that kind of fair value gap? The narrative leans heavily on future revenue growth, margin reset, and stronger free cash flow doing the heavy lifting. The exact mix of those three levers is what really drives that $45.09 number.
Result: Fair Value of $45.09 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, integration setbacks from recent acquisitions or delays in key tech launches like Arvis could quickly challenge the idea that current pricing appears overly pessimistic.
Find out about the key risks to this Enovis narrative.
Next Steps
Given the mixed sentiment here, it makes sense to look at the numbers yourself and decide quickly where you stand, especially as our work highlights 4 key rewards that investors are already watching closely.
Looking for more investment ideas?
If Enovis has sharpened your thinking, do not stop here. Use the screener to quickly scan other stocks that might fit your approach before the crowd catches on.
- Target dependable income by checking out 16 dividend fortresses that could appeal if you prioritise regular cash returns.
- Hunt for potential mispriced opportunities through 50 high quality undervalued stocks that pair quality fundamentals with prices that some investors might be overlooking.
- Focus on resilience first and review 66 resilient stocks with low risk scores if you want companies where balance sheets and risk scores are front and centre.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com